LymphedemaV1, Pmc, Corpus, bibRecord, 002E54

Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma

Identifieur interne : 002E54 ( Pmc/Corpus ); précédent : 002E53; suivant : 002E55

Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma

Auteurs : Wei Ma ; Kai Wang ; Shaoqi Yang ; Jianbo Wang ; Bingxu Tan ; Bing Bai ; Nana Wang ; Yibin Jia ; Ming Jia ; Yufeng Cheng

Source :

International Journal of Clinical and Experimental Pathology [ 1936-2625 ] ; 2014.

RBID : PMC:4069902

Abstract

Backgroud and aim: Podoplanin (D2-40) is a specific marker for lymphatic endothelium. The vast majority of previous studies on podoplanin immunostaining in esophageal squamous cell carcinoma (ESCC) focused on identifying lymphatic vessel invasion (LVI) and counting lymphatic vessel density (LVD) and had contradictory results. Recent studies show podoplanin expression on cancer cells or tumor stroma in several cancers, which have specific significance; but the status in ESCC remains unclear. Therefore, the aim of this study was to further study and summarize the clinicopathological significance of podoplanin immunoreactivity in ESCC. Materials and methods: We examined podoplanin expression in tissue specimens from 107 patients with ESCC by immunohistochemistry. Podoplanin positive lymphatic vessels in intratumoral and peritumoral tissues and podoplanin positive expression in cancer cells and tumor stroma were analyzed, and correlated with clinicopathologic parameters and three-year overall and free-disease survival. Results: 34 (31.8%) and 28 (26.2%) of 107 specimens had podoplanin positive expression in cancer cells and tumor stroma, respectively. Logistic regression analysis showed high intratumoral lymphatic vessel density (I-LVD) and podoplanin positivity in cancer cells were increased risks of lymph node metastasis (LNM) (OR = 2.45, P = 0.03; OR = 0.35, P = 0.01, respectively). Survival analysis showed that I-LVD was a significant factor related to poor three-year overall and free-disease survival (P = 0.04, P = 0.03, respectively). Conclusions: Previous data and our results show that podoplanin seems to be a useful marker to predict LNM, recurrence, and worse prognosis in ESCC; in particular, LVI, high I-LVD, and podoplanin positivity in cancer cells are associated with LNM, recurrence and overall survival.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069902

PubMed: 24966946
PubMed Central: 4069902

Links to Exploration step

PMC:4069902

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma</title>
<author><name sortKey="Ma, Wei" sort="Ma, Wei" uniqKey="Ma W" first="Wei" last="Ma">Wei Ma</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="au2"><institution>Department of Radiation Oncology, Cancer Hospital, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Kai" sort="Wang, Kai" uniqKey="Wang K" first="Kai" last="Wang">Kai Wang</name>
<affiliation><nlm:aff id="au3"><institution>Department of Oncology, Wendeng Central Hospital</institution>
<addr-line>Weihai, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yang, Shaoqi" sort="Yang, Shaoqi" uniqKey="Yang S" first="Shaoqi" last="Yang">Shaoqi Yang</name>
<affiliation><nlm:aff id="au4"><institution>Department of Digestive Disease, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Jianbo" sort="Wang, Jianbo" uniqKey="Wang J" first="Jianbo" last="Wang">Jianbo Wang</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tan, Bingxu" sort="Tan, Bingxu" uniqKey="Tan B" first="Bingxu" last="Tan">Bingxu Tan</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bai, Bing" sort="Bai, Bing" uniqKey="Bai B" first="Bing" last="Bai">Bing Bai</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Nana" sort="Wang, Nana" uniqKey="Wang N" first="Nana" last="Wang">Nana Wang</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jia, Yibin" sort="Jia, Yibin" uniqKey="Jia Y" first="Yibin" last="Jia">Yibin Jia</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jia, Ming" sort="Jia, Ming" uniqKey="Jia M" first="Ming" last="Jia">Ming Jia</name>
<affiliation><nlm:aff id="au5"><institution>Department of Pathology, Medical College of Shandong University</institution>
<addr-line>Jinan, Shandong, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cheng, Yufeng" sort="Cheng, Yufeng" uniqKey="Cheng Y" first="Yufeng" last="Cheng">Yufeng Cheng</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24966946</idno>
<idno type="pmc">4069902</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069902</idno>
<idno type="RBID">PMC:4069902</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">002E54</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002E54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma</title>
<author><name sortKey="Ma, Wei" sort="Ma, Wei" uniqKey="Ma W" first="Wei" last="Ma">Wei Ma</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="au2"><institution>Department of Radiation Oncology, Cancer Hospital, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Kai" sort="Wang, Kai" uniqKey="Wang K" first="Kai" last="Wang">Kai Wang</name>
<affiliation><nlm:aff id="au3"><institution>Department of Oncology, Wendeng Central Hospital</institution>
<addr-line>Weihai, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yang, Shaoqi" sort="Yang, Shaoqi" uniqKey="Yang S" first="Shaoqi" last="Yang">Shaoqi Yang</name>
<affiliation><nlm:aff id="au4"><institution>Department of Digestive Disease, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Jianbo" sort="Wang, Jianbo" uniqKey="Wang J" first="Jianbo" last="Wang">Jianbo Wang</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tan, Bingxu" sort="Tan, Bingxu" uniqKey="Tan B" first="Bingxu" last="Tan">Bingxu Tan</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bai, Bing" sort="Bai, Bing" uniqKey="Bai B" first="Bing" last="Bai">Bing Bai</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wang, Nana" sort="Wang, Nana" uniqKey="Wang N" first="Nana" last="Wang">Nana Wang</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jia, Yibin" sort="Jia, Yibin" uniqKey="Jia Y" first="Yibin" last="Jia">Yibin Jia</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jia, Ming" sort="Jia, Ming" uniqKey="Jia M" first="Ming" last="Jia">Ming Jia</name>
<affiliation><nlm:aff id="au5"><institution>Department of Pathology, Medical College of Shandong University</institution>
<addr-line>Jinan, Shandong, China</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cheng, Yufeng" sort="Cheng, Yufeng" uniqKey="Cheng Y" first="Yufeng" last="Cheng">Yufeng Cheng</name>
<affiliation><nlm:aff id="au1"><institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">International Journal of Clinical and Experimental Pathology</title>
<idno type="eISSN">1936-2625</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Backgroud and aim: Podoplanin (D2-40) is a specific marker for lymphatic endothelium. The vast majority of previous studies on podoplanin immunostaining in esophageal squamous cell carcinoma (ESCC) focused on identifying lymphatic vessel invasion (LVI) and counting lymphatic vessel density (LVD) and had contradictory results. Recent studies show podoplanin expression on cancer cells or tumor stroma in several cancers, which have specific significance; but the status in ESCC remains unclear. Therefore, the aim of this study was to further study and summarize the clinicopathological significance of podoplanin immunoreactivity in ESCC. Materials and methods: We examined podoplanin expression in tissue specimens from 107 patients with ESCC by immunohistochemistry. Podoplanin positive lymphatic vessels in intratumoral and peritumoral tissues and podoplanin positive expression in cancer cells and tumor stroma were analyzed, and correlated with clinicopathologic parameters and three-year overall and free-disease survival. Results: 34 (31.8%) and 28 (26.2%) of 107 specimens had podoplanin positive expression in cancer cells and tumor stroma, respectively. Logistic regression analysis showed high intratumoral lymphatic vessel density (I-LVD) and podoplanin positivity in cancer cells were increased risks of lymph node metastasis (LNM) (OR = 2.45, <italic>P</italic>
 = 0.03; OR = 0.35, <italic>P</italic>
 = 0.01, respectively). Survival analysis showed that I-LVD was a significant factor related to poor three-year overall and free-disease survival (<italic>P</italic>
 = 0.04, <italic>P</italic>
 = 0.03, respectively). Conclusions: Previous data and our results show that podoplanin seems to be a useful marker to predict LNM, recurrence, and worse prognosis in ESCC; in particular, LVI, high I-LVD, and podoplanin positivity in cancer cells are associated with LNM, recurrence and overall survival.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Exp Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Clin Exp Pathol</journal-id>
<journal-id journal-id-type="publisher-id">ijcep</journal-id>
<journal-title-group><journal-title>International Journal of Clinical and Experimental Pathology</journal-title>
</journal-title-group>
<issn pub-type="epub">1936-2625</issn>
<publisher><publisher-name>e-Century Publishing Corporation</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">24966946</article-id>
<article-id pub-id-type="pmc">4069902</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Ma</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
<xref ref-type="aff" rid="au2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wang</surname>
<given-names>Kai</given-names>
</name>
<xref ref-type="aff" rid="au3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Yang</surname>
<given-names>Shaoqi</given-names>
</name>
<xref ref-type="aff" rid="au4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wang</surname>
<given-names>Jianbo</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tan</surname>
<given-names>Bingxu</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bai</surname>
<given-names>Bing</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wang</surname>
<given-names>Nana</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Jia</surname>
<given-names>Yibin</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Jia</surname>
<given-names>Ming</given-names>
</name>
<xref ref-type="aff" rid="au5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Cheng</surname>
<given-names>Yufeng</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<aff id="au1"><label>1</label>
<institution>Department of Radiation Oncology, Qilu Hospital of Shandong University</institution>
<addr-line>Jinan, China</addr-line>
</aff>
<aff id="au2"><label>2</label>
<institution>Department of Radiation Oncology, Cancer Hospital, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</aff>
<aff id="au3"><label>3</label>
<institution>Department of Oncology, Wendeng Central Hospital</institution>
<addr-line>Weihai, China</addr-line>
</aff>
<aff id="au4"><label>4</label>
<institution>Department of Digestive Disease, General Hospital of Ningxia Medical University</institution>
<addr-line>Yinchuan, China</addr-line>
</aff>
<aff id="au5"><label>5</label>
<institution>Department of Pathology, Medical College of Shandong University</institution>
<addr-line>Jinan, Shandong, China</addr-line>
</aff>
</contrib-group>
<author-notes><corresp><bold>Address correspondence to:</bold>
 Dr. Yufeng Cheng, Department of Radiation Oncology, Qilu Hospital of Shandong University, 107 Wenhua Road West, Jinan, Shandong, China. Tel: +86-0531-82169520; Fax: +86-0531-82169520; E-mail: <email>qilucyf@126.com</email>
</corresp>
</author-notes>
<pub-date pub-type="collection"><year>2014</year>
</pub-date>
<pub-date pub-type="epub"><day>15</day>
<month>4</month>
<year>2014</year>
</pub-date>
<volume>7</volume>
<issue>5</issue>
<fpage>2361</fpage>
<lpage>2371</lpage>
<history><date date-type="received"><day>28</day>
<month>2</month>
<year>2014</year>
</date>
<date date-type="accepted"><day>04</day>
<month>4</month>
<year>2014</year>
</date>
</history>
<permissions><copyright-statement>IJCEP Copyright © 2014</copyright-statement>
<copyright-year>2014</copyright-year>
</permissions>
<abstract><p>Backgroud and aim: Podoplanin (D2-40) is a specific marker for lymphatic endothelium. The vast majority of previous studies on podoplanin immunostaining in esophageal squamous cell carcinoma (ESCC) focused on identifying lymphatic vessel invasion (LVI) and counting lymphatic vessel density (LVD) and had contradictory results. Recent studies show podoplanin expression on cancer cells or tumor stroma in several cancers, which have specific significance; but the status in ESCC remains unclear. Therefore, the aim of this study was to further study and summarize the clinicopathological significance of podoplanin immunoreactivity in ESCC. Materials and methods: We examined podoplanin expression in tissue specimens from 107 patients with ESCC by immunohistochemistry. Podoplanin positive lymphatic vessels in intratumoral and peritumoral tissues and podoplanin positive expression in cancer cells and tumor stroma were analyzed, and correlated with clinicopathologic parameters and three-year overall and free-disease survival. Results: 34 (31.8%) and 28 (26.2%) of 107 specimens had podoplanin positive expression in cancer cells and tumor stroma, respectively. Logistic regression analysis showed high intratumoral lymphatic vessel density (I-LVD) and podoplanin positivity in cancer cells were increased risks of lymph node metastasis (LNM) (OR = 2.45, <italic>P</italic>
 = 0.03; OR = 0.35, <italic>P</italic>
 = 0.01, respectively). Survival analysis showed that I-LVD was a significant factor related to poor three-year overall and free-disease survival (<italic>P</italic>
 = 0.04, <italic>P</italic>
 = 0.03, respectively). Conclusions: Previous data and our results show that podoplanin seems to be a useful marker to predict LNM, recurrence, and worse prognosis in ESCC; in particular, LVI, high I-LVD, and podoplanin positivity in cancer cells are associated with LNM, recurrence and overall survival.</p>
</abstract>
<kwd-group><kwd>Podoplanin</kwd>
<kwd>esophagus</kwd>
<kwd>immunohistochemistry</kwd>
<kwd>squamous cell carcinoma</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E54 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002E54 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:4069902
   |texte=   Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:24966946" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma

Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki